Hind.Organ.Chem.

Why is Hindustan Organic Chemicals Ltd falling/rising?

As of 06-Aug, Hindustan Organic Chemicals Ltd's stock price is at 40.26, down 1.08% over the last two days and underperforming its sector. Despite a year-to-date increase of 26.05%, recent declines and reduced investor participation indicate a downward trend in the stock's price.

As of 06-Aug, Hindustan Organic Chemicals Ltd's stock price is currently at 40.26, reflecting a decrease of 0.44, or 1.08%. The stock has been experiencing a consecutive decline over the last two days, resulting in a total drop of 3.46% during this period. Additionally, the stock has underperformed its sector by 2.86% today. <BR><BR>Despite these recent declines, it is noteworthy that the stock has shown strong performance over longer periods, with a year-to-date increase of 26.05%, significantly outperforming the Sensex, which has decreased by 7.35% in the same timeframe. However, the current trend indicates a falling investor participation, as evidenced by a 12.86% drop in delivery volume compared to the 5-day average. <BR><BR>Moreover, while the stock is trading above its moving averages across various time frames, the recent negative performance and declining investor interest suggest that the stock's price is currently falling.

Which are the latest news on Hind.Organ.Chem.?

When is the next results date for Hindustan Organic Chemicals Ltd?

The next results date for Hindustan Organic Chemicals Ltd is August 7, 2026.

The next results date for Hindustan Organic Chemicals Ltd is scheduled for August 7, 2026.

How big is Hind.Organ.Chem.?

As of 10th June, Hindustan Organic Chemicals Ltd has a market capitalization of 256.00 Cr and reported Net Sales of 573.76 Cr, with a Net Profit loss of 12.71 Cr over the latest four quarters.

As of 10th June, Hindustan Organic Chemicals Ltd has a market capitalization of 256.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 573.76 Cr. However, it experienced a loss of 12.71 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 1,045.34 Cr and Total Assets were valued at 1,564.37 Cr.

Who are in the management team of Hind.Organ.Chem.?

The management team of Hind.Organ.Chem. includes Sajeev B (Chairman & Managing Director), Bharat J. Kanabar and Pratyush Mandal (Non Official Independent Directors), Subramonian H (Company Secretary), Yogendra Prasad Shukla (Director of Finance & CFO), and several government nominees: Satendra Singh, Kanisk Kant Srivastava, and Sanjay Rastogi.

The management team of Hind.Organ.Chem. includes the following individuals:<BR><BR>1. **Sajeev B** - Chairman & Managing Director<BR>2. **Bharat J. Kanabar** - Non Official Independent Director<BR>3. **Pratyush Mandal** - Non Official Independent Director<BR>4. **Subramonian H** - Company Secretary & Compliance Officer<BR>5. **Yogendra Prasad Shukla** - Director (Finance) & CFO<BR>6. **Satendra Singh** - Nominee (Government)<BR>7. **Kanisk Kant Srivastava** - Nominee (Government)<BR>8. **Sanjay Rastogi** - Nominee (Government)<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

Who are the peers of the Hind.Organ.Chem.?

Peers of Hind.Organ.Chem. include Lords Chloro, Kanoria Chem., Mangalam Organic, Alufluoride, National Perox., Genus Prime, ZR2 Bioenergy, Kesar Petroprod., and IVP. Hind.Organ.Chem. has a 1-year return of 3.76%, lower than Alufluoride's 13.80% and higher than ZR2 Bioenergy's -68.86%.

Peers: The peers of Hind.Organ.Chem. are Lords Chloro, Kanoria Chem., Mangalam Organic, Alufluoride, National Perox., Genus Prime, ZR2 Bioenergy, Kesar Petroprod., and IVP.<BR><BR>Quality Snapshot: Excellent management risk is observed at Alufluoride, while Average management risk is found at Lords Chloro, National Perox., and Kesar Petroprod., and the rest. Below Average management risk is noted for Kanoria Chem., Mangalam Organic, Hind.Organ.Chem., Genus Prime, ZR2 Bioenergy, and IVP. Growth is rated as Good for Alufluoride, Lords Chloro, and Kesar Petroprod., while Below Average growth is seen in Kanoria Chem., Mangalam Organic, Hind.Organ.Chem., National Perox., ZR2 Bioenergy, and IVP, and the rest. Capital Structure is rated as Good for Alufluoride and Average for Lords Chloro, National Perox., and IVP, while Below Average is noted for Kanoria Chem., Mangalam Organic, Hind.Organ.Chem., Genus Prime, ZR2 Bioenergy, and Kesar Petroprod., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Alufluoride at 13.80%, while ZR2 Bioenergy has the lowest at -68.86%. Hind.Organ.Chem.'s 1-year return is 3.76%, which is higher than ZR2 Bioenergy's but lower than Alufluoride's. Additionally, the six-month return is negative for ZR2 Bioenergy and Kesar Petroprod.

What does Hind.Organ.Chem. do?

Hindustan Organic Chemicals Ltd is a micro-cap company that produces bulk industrial chemicals and intermediates, established in 1960 to promote self-reliance in organic chemicals. As of March 2026, it reported net sales of 136 Cr and a net profit of 16 Cr.

Overview: <BR>Hindustan Organic Chemicals Ltd is engaged in the business of bulk industrial chemicals and chemical intermediates within the commodity chemicals industry, categorized as a micro-cap company.<BR><BR>History: <BR>Incorporated in 1960 by the Government of India, Hindustan Organic Chemicals Ltd was established to achieve self-reliance in basic organic chemicals needs. Initially starting as a small chemical unit, it has grown into a multi-unit company with two fast-growing units and one subsidiary. The latest reported quarterly results show net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 136 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 16 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 256 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 42 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.03 <BR>Return on Equity: -1.92% <BR>Price to Book: 0.25 <BR><BR>Contact Details: <BR>Address: 401 402 403 4th Flr V Times Sq, Plot No 3 Sec-15 CBD Belapur Navi Mumbai Maharashtra : 400614 <BR>Tel: 91-22-27575268/69 <BR>Email: rasayani.cs@hocl.gov.in <BR>Website: http://www.hocl.gov.in

Should I buy, sell or hold Hindustan Organic Chemicals Ltd?

Are Hindustan Organic Chemicals Ltd latest results good or bad?

Hindustan Organic Chemicals Ltd's latest results show a significant quarterly profit increase of 500.51% to ₹15.70 crore, but a 7.39% decline in net sales and ongoing operational challenges indicate mixed performance. While the profit improvement is positive, concerns about revenue volatility and fundamental weaknesses remain.

Hindustan Organic Chemicals Ltd's latest results present a mixed picture. On one hand, the company reported a significant increase in net profit for Q4 FY26, achieving ₹15.70 crore, which is a remarkable 500.51% improvement quarter-on-quarter. This turnaround in profitability is primarily attributed to a reduction in interest expenses and better operating performance.<BR><BR>However, when looking at net sales, the company experienced a decline of 7.39% compared to the previous quarter, totaling ₹136.36 crore. This decline continues a trend of revenue volatility, as sales were nearly flat year-on-year as well. Furthermore, the full-year performance reveals persistent operational challenges, with an operating loss of ₹86 crore for FY25, indicating that the company has struggled significantly over the longer term.<BR><BR>While the operating margin improved to 12.21% from a negative margin in the previous quarter, the overall financial health of the company raises concerns. The negative return on equity and return on capital employed further highlight the fundamental weaknesses in its business model.<BR><BR>In summary, while the quarterly profit improvement is a positive sign, it is overshadowed by ongoing operational struggles and revenue declines. Therefore, the latest results can be seen as a cautious positive, but the broader context suggests significant challenges remain.

How has been the historical performance of Hind.Organ.Chem.?

Hind.Organ.Chem. experienced significant fluctuations in financial performance, with net sales declining from INR 703.89 crore in March 2024 to INR 535.87 crore in March 2025, while profitability improved markedly, resulting in a profit after tax of INR 391.54 crore in March 2025 compared to a loss the previous year. Despite challenges, the company showed resilience with a positive cash flow turnaround.

Answer:<BR>The historical performance of Hind.Organ.Chem. shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Hind.Organ.Chem. experienced a decline in net sales from INR 703.89 crore in March 2024 to INR 535.87 crore in March 2025, following a peak of INR 631.44 crore in March 2023. The total operating income mirrored this trend, decreasing to INR 535.87 crore in March 2025 from INR 703.89 crore in the previous year. The company faced rising raw material costs, which were INR 426.95 crore in March 2025, up from INR 503.05 crore in March 2024. Operating profit (PBDIT) turned negative, recording -INR 63.38 crore in March 2025, a stark contrast to the positive INR 15.70 crore in March 2024. Profit before tax also improved significantly to INR 394.87 crore in March 2025 from a loss of -INR 55.32 crore in March 2024, leading to a profit after tax of INR 391.54 crore in March 2025, compared to a loss of -INR 55.32 crore the previous year. The company's total assets decreased slightly to INR 1,564.37 crore in March 2025 from INR 1,572.34 crore in March 2024, while total liabilities also saw a reduction to INR 1,564.37 crore from INR 1,572.34 crore. Cash flow from operating activities showed a positive turnaround, reaching INR 631 crore in March 2025, compared to a negative cash flow of -INR 65 crore in March 2024. Overall, the company has shown resilience with a notable recovery in profitability despite challenges in sales and operating margins.

Is Hind.Organ.Chem. overvalued or undervalued?

Hind.Organ.Chem. is currently assessed as undervalued and risky, with key ratios indicating financial distress, contrasting sharply with competitors like Solar Industries and Godrej Industries, making it a potential buying opportunity for risk-tolerant investors despite a year-to-date stock decline of 15.24%.

As of 1 November 2021, Hind.Organ.Chem. has moved from a valuation grade of very expensive to risky. The company is currently assessed as undervalued. Key ratios include a PE ratio of -2.15, an EV to EBITDA of -2.14, and an EV to Sales of 0.34, which indicate significant financial distress compared to its peers.<BR><BR>In comparison, Solar Industries, rated very expensive, has a PE ratio of 123.77, while Godrej Industries, rated attractive, has a PE ratio of 46.63. These ratios highlight the stark contrast in valuation between Hind.Organ.Chem. and its competitors. Despite recent stock performance showing a decline of 15.24% year-to-date compared to a 5.63% gain in the Sensex, the company's low valuation ratios suggest it may present a buying opportunity for investors willing to take on higher risk.

What is the technical trend for Hind.Organ.Chem.?

As of May 20, 2025, Hind.Organ.Chem. shows a mildly bearish trend, with daily indicators indicating bearish momentum despite some weekly bullish signals.

As of 20 May 2025, the technical trend for Hind.Organ.Chem. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating bearish momentum. The weekly MACD is mildly bullish, but the monthly MACD and Bollinger Bands are both bearish, suggesting weakness in the longer term. The RSI on a monthly basis is also bearish, reinforcing the negative outlook. Overall, while there are some bullish signals on the weekly indicators, the prevailing trend remains bearish, particularly in the daily and monthly assessments.

Who are the top shareholders of the Hind.Organ.Chem.?

The top shareholders of Hind.Organ.Chem. include the President of India with a 58.78% stake, while individual investors hold 34.63%. There are no pledged promoter holdings, mutual funds, or foreign institutional investors involved.

The top shareholders of Hind.Organ.Chem. are primarily the promoters, with the President of India holding the largest stake at 58.78%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. Additionally, individual investors hold 34.63% of the shares. There are no significant public shareholders listed.

Has Hind.Organ.Chem. declared dividend?

No Dividend History Available